Time filter

Source Type

Maastricht, Netherlands

Maastricht University and Academisch Ziekenhuis Maastricht | Date: 2013-09-12

The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled-1 and/or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.

Maastricht University and Academisch Ziekenhuis Maastricht | Date: 2010-03-16

The invention relates to a method for the classification of cancer using a specific multi-class tumor classifier comprising specific sets of genes for the interpretation of expression data obtained from tumor samples. More specifically, the method of the present invention provides an accurate, reproducible, robust, objective and easy to perform method for determining the primary site of a Cancer of Unknown Primary site (CUP). For this purpose, the method provides that a classifier parameter is determined by comparing an expression profile of a tumor sample with a template profile representative for a particular primary site of a cancer.

Rikilt, Academisch Ziekenhuis Maastricht and Maastricht University | Date: 2013-09-16

The invention is in the field of molecular diagnostics. More in particular it provides marker genes for determining the immunotoxicity of compounds. A method according to the invention employs samples obtained from a cell exposed to a potentially immunotoxic compound and determines expression levels of a number of marker genes in order to distinguish between immunotoxic compounds and non-immunotoxic compounds. More in particular, the invention relates to an in vitro method for determining whether a compound is immunotoxic wherein the expression level of at least one marker gene is determined in a sample obtained from a nucleated cell exposed to the compound, wherein the at least one marker gene is selected from the group consisting of ABCA1, CHAC1, CRIM1 and HMGCS1, and wherein it is concluded that the compound is immunotoxic if the expression level of said at least one marker gene is below or above a predetermined reference value.

Maastricht University, Rijksinstituut Voor Volksgezondheid En Milieu and Academisch Ziekenhuis Maastricht | Date: 2013-04-17

This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic.

Maastricht University and Academisch Ziekenhuis Maastricht | Date: 2013-08-27

The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.

Discover hidden collaborations